BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: A selective BCL2 inhibitor, ABT-199 known as Venetoclax, is demonstrated to have a strong antileukemic effect against several hematological malignances such as chronic lymphocytic leukemia, acute myeloid leukemia and in-vitro and in-vivo CML models where this cytotoxicity improves the BCR-ABL1 inhibitors efficacy [14,15,16,17,18,19].